Evaluation of risperidone efficacy versus placebo in treatment of obsessive compulsive disorder symptoms in bipolar patients
Phase 3
Recruiting
- Conditions
- ?????? ?????? ????-?????? ??????.Obsessive-compulsive disorder
- Registration Number
- IRCT20140926019295N3
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
DSM-5 criteria for Bipolar disorder type 1 or 2
yale-brown score higher than 61
Coincidence of Bipolar disorder and obsessive-compulsive disorder
Exclusion Criteria
Acute phase of mania or depression
Major medical conditions(cardiovascular-respiratory-renal-digestive)
Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Obsessional symptoms. Timepoint: 4 and 8 weeks after receiving risperidone. Method of measurement: yale brown questionnaire.
- Secondary Outcome Measures
Name Time Method